Free tools Windows power users keep installed
One-click scans. No signup required.
Not yet. Manganese-doped carbon nanodots (MnCNDs) are promising experimental probes: a 2026 study reported fluorescence, MRI-related properties and T1-weighted imaging in mice. But the evidence is preclinical, not proof that these particles can replace clinically used contrast agents. No human clinical validation or approval is established by the cited studies.
What are manganese-doped carbon nanodots?
Carbon nanodots are very small carbon-based particles that can fluoresce. In MnCNDs, manganese is incorporated into the material to add magnetic properties relevant to MRI. The research aim is to combine optical imaging, which can provide fluorescence signals, with MRI in one probe.
That combination could be useful in research, but fluorescence plus MRI activity does not by itself establish a practical clinical agent. Performance and safety depend on the particular formulation, how it is made and purified, how it behaves in the body, and the imaging conditions.
What did the 2026 study find?
Purified particles and imaging properties
Cesco and colleagues reported a rapid microwave-assisted hydrothermal synthesis using manganese chloride tetrahydrate and organic precursors, followed by size-exclusion chromatography purification. The purified nanodots contained 5% (w/w) Mn(II). The authors described an amorphous carbon structure with a metal-enriched core and excitation-dependent fluorescence. They also reported efficient cellular uptake in vitro and longitudinal relaxivity that remained stable over seven days.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
Mouse imaging and distribution
The study reported T1-weighted MRI in mice. In its animal biodistribution assessment, the material was observed mainly in the liver, spleen and kidneys. The authors described findings consistent with hepatic and renal elimination pathways, as well as potential excretion through salivary glands. These observations concern that study’s formulation and animals; they do not establish how the material would distribute or clear in people.
How do the reported Mn-CND studies compare?
These are different formulations tested in different experiments, not successive measurements of a single product. Relaxivity describes how an agent changes water-proton relaxation rates: r1 is associated with longitudinal relaxation and T1-weighted imaging, while r2 is associated with transverse relaxation and T2-weighted imaging.
Rank #2
| Study and formulation | Reported findings | How to interpret the result |
|---|---|---|
| Cesco et al., ACS Nano, 2026; purified MnCNDs | 5% (w/w) Mn(II); seven days of reported stable longitudinal relaxivity; T1-weighted mouse MRI | Preclinical imaging evidence for this formulation; the available study description does not provide a numerical relaxivity value. |
| α-ketoglutaric-acid-derived Mn-CNDs, Nanoscale, 2025 | Average particle size 1.9 nm and 6% manganese. At 1 T, r1 was 5.46 s−1 mM−1 and r2 was 46.83 s−1 mM−1. The paper’s Gadoterate comparator values were r1 3.58 and r2 21.6 s−1 mM−1, measured at 0.5 T. | The field strengths differ, so these figures are not a same-condition head-to-head demonstration that the nanodots outperform Gadoterate. The authors discuss potential T2-weighted contrast and fluorescence. |
| Earlier Mn(II)-doped CND report; thermal decomposition of a diphenylhydantoin–Mn(II) complex | In-vitro MRI and fluorescence experiments; the report describes T2 contrast potential and relaxivity higher than commercial agents under its study conditions. | Its cell findings varied by line: the abstract reported good viability in malignant melanoma lines over a broad concentration range, but cytotoxic effects in MG-63 osteosarcoma and breast adenocarcinoma lines. |
A relaxivity number is not a stand-alone measure of diagnostic performance. Comparisons depend on factors including field strength, MRI sequence, dose, formulation, water accessibility, particle behavior and biological distribution. The 2025 Gadoterate figures, in particular, were measured at a different field strength from the Mn-CND figures.
Are manganese carbon nanodots safe for MRI patients?
The cited evidence does not establish safety for patients. In the 2026 study, the authors reported no histological tissue damage in their assessment and no relevant long-term toxicity over four weeks in animals. Those are limited, study-specific animal observations—not proof of human safety, long-term clearance or lower risk than existing agents.
Rank #3
The earlier in-vitro report also cautions against describing MnCNDs as uniformly biocompatible: its cytotoxicity findings differed among cell lines. Cell results cannot settle human safety, but they show why safety claims must stay tied to the particular formulation and test conditions.
Could they replace gadolinium-based contrast agents?
The studies do not show that MnCNDs can replace gadolinium-based contrast agents (GBCAs) in clinical practice. FDA patient information describes intravenous GBCAs as an option used for some MRI exams, and FDA safety information addresses gadolinium retention. That concern does not demonstrate that experimental manganese nanodots are safer or more effective; the cited MnCND work has not established a clinically available alternative.
Rank #4
- Used Book in Good Condition
A separate FDA orphan-designation record concerns a manganese chloride formulation proposed for a liver-lesion indication. It is a different product from the carbon nanodots discussed here, and the record says that formulation is not FDA-approved for that orphan indication. Orphan designation should not be mistaken for approval or for regulatory status of MnCNDs.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What evidence would establish clinical potential?
Before a comparison with available contrast agents could support a clinical claim, studies would need to make the relevant conditions and outcomes directly comparable. Important details include:
- Whether the candidate is intended for T1- or T2-weighted imaging, with r1 and r2 measured at the same field strength and temperature.
- The exact particle formulation, size, manganese loading, purification method and evidence that unbound manganese has been removed.
- The administered dose, MRI sequence and imaging results, rather than relaxivity alone.
- Fluorescence performance if multimodal imaging is claimed, alongside biodistribution, clearance and safety assessments.
- Evidence progressing beyond cells and animals, including human trials and regulatory review.
Until such evidence exists, MnCNDs are best understood as a developing preclinical research direction—not a contrast agent patients can choose for an MRI scan.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
